Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophreniaVidya Perera, Andrew J. McLachlan, Thomas M. Polasek et al.|Expert Opinion on Drug Metabolism & Toxicology|2013Cited by 39